Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
yahoo.com
finance
2022-06-03 20:30:00

Surface Oncology, Inc.

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that the company granted non-qualified stock options to two new employees to purchase an aggregate of 23,600 shares of the company's common stock with a per share exercise price of $1.72, the closing price of Surface's common stock as reported by Nasdaq on June 1, 2022, the date of grant.
